In: Supportive Care in Cancer, 2015, vol. 23, no. 2, p. 525-545
|
In: Gynäkologische Endokrinologie, 2015, vol. 13, no. 3, p. 201-205
|
|
|
In: Oncogene, 2019, vol. 38, no. 15, p. 2814–2829
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental...
|
In: Annals of Hematology, 2010, vol. 89, no. 8, p. 783-787
|
In: Osteoporosis International, 2013, vol. 24, no. 12, p. 2929-2953
|
In: Supportive Care in Cancer, 2006, vol. 14, no. 9, p. 901-909
|
In: Supportive Care in Cancer, 2008, vol. 16, no. 4, p. 339-345
|
In: Virchows Archiv, 2005, vol. 446, no. 2, p. 136-141
|